Pfizer (NYSE:PFE)‘s stock had its “neutral” rating reaffirmed by research analysts at Berenberg Bank in a report released on Wednesday. They presently have a $37.00 price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price objective would suggest a potential upside of 1.87% from the stock’s previous close.
Several other research analysts have also recently weighed in on PFE. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, April 6th. UBS set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Leerink Swann upped their price objective on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a research report on Wednesday, January 31st. BMO Capital Markets set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, March 6th. Finally, Barclays cut Pfizer from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $41.00 to $38.00 in a research report on Thursday, April 5th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $39.25.
PFE stock opened at $36.32 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. The stock has a market cap of $214,005.48, a PE ratio of 13.71, a PEG ratio of 1.79 and a beta of 0.90. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43.
Pfizer announced that its board has initiated a stock repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.
In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the sale, the insider now owns 36,959 shares in the company, valued at $1,374,505.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mikael Dolsten sold 69,699 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $36.59, for a total value of $2,550,286.41. Following the completion of the sale, the insider now owns 120,784 shares in the company, valued at approximately $4,419,486.56. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock worth $9,064,785 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Earnest Partners LLC bought a new position in shares of Pfizer during the fourth quarter worth approximately $105,000. First Dallas Securities Inc. bought a new position in shares of Pfizer during the fourth quarter worth approximately $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new position in shares of Pfizer during the fourth quarter worth approximately $118,000. Delpha Capital Management LLC bought a new position in shares of Pfizer during the fourth quarter worth approximately $126,000. Finally, Americafirst Capital Management LLC bought a new position in shares of Pfizer during the third quarter worth approximately $127,000. Hedge funds and other institutional investors own 71.21% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/13/pfizer-pfe-stock-rating-reaffirmed-by-berenberg-bank.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.